AstraZeneca Pharma India (NSE:ASTRAZEN) ROCE %: 23.90% (As of Mar. 2026)


NSE:ASTRAZEN AstraZeneca Pharma India Ltd NSE:ASTRAZEN
92 GF Score
Price ₹8,391.00
GF Value ₹10,868.58
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is AstraZeneca Pharma India ROCE %?

AstraZeneca Pharma India NSE:ASTRAZEN -0.60% 92 ROCE % is 23.90% as of Mar. 2026. GuruFocus rates NSE:ASTRAZEN with a GF Score™ of 92/100 and a GF Value™ of ₹10,868.58 (Modestly Undervalued). The stock has 4 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. AstraZeneca Pharma India's annualized ROCE % for the quarter that ended in Mar. 2026 was 23.90%.

AstraZeneca Pharma India  (NSE:ASTRAZEN) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

AstraZeneca Pharma India ROCE % Related Terms

AstraZeneca Pharma India ROCE % Historical Data

* Premium members only.

The historical data trend for AstraZeneca Pharma India's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AstraZeneca Pharma India ROCE % Chart

AstraZeneca Pharma India Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 16.88 23.96 33.40 20.55 28.17

AstraZeneca Pharma India Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 38.84 37.01 35.12 22.74 23.90
NSE:ASTRAZEN
92GF Score
AstraZeneca Pharma India Ltd NSE:ASTRAZEN
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

AstraZeneca Pharma India ROCE % Calculation

AstraZeneca Pharma India's annualized ROCE % for the fiscal year that ended in Mar. 2026 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Mar. 2026 )  (A: Mar. 2025 )(A: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Mar. 2026 )  (A: Mar. 2025 )(A: Mar. 2026 )
=2566.9/( ( (15181.2 - 7030) + (19891 - 9818.1) )/ 2 )
=2566.9/( (8151.2+10072.9)/ 2 )
=2566.9/9112.05
=28.17 %

AstraZeneca Pharma India's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=2407.2/( ( (0 - 0) + (19891 - 9818.1) )/ 1 )
=2407.2/( ( 0 + 10072.9 )/ 1 )
=2407.2/10072.9
=23.90 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 23.90% mean?
AstraZeneca Pharma India (NSE:ASTRAZEN) has a ROCE % of 23.90% as of Mar. 2026.
Is AstraZeneca Pharma India's ROCE % too high?
AstraZeneca Pharma India's current ROCE % is 23.90%. The Drug Manufacturers industry median ROCE % is 7.00. AstraZeneca Pharma India's value of 23.90% is 241.7% above this industry median. Overall, AstraZeneca Pharma India has a GF Score™ of 92/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does AstraZeneca Pharma India's ROCE % compare to ZTS?
AstraZeneca Pharma India's ROCE % of 23.90% can be compared against companies in the Drug Manufacturers industry. The industry median ROCE % is 7.00. AstraZeneca Pharma India's value of 23.90% is 241.7% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Drug Manufacturers company?
The median ROCE % among Drug Manufacturers companies is 7.00, based on 958 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. AstraZeneca Pharma India's current ROCE % of 23.90% is 241.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median ROCE % is 7.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. AstraZeneca Pharma India's current ROCE % is 23.90%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AstraZeneca Pharma India stock overvalued right now?
Based on GuruFocus' analysis, AstraZeneca Pharma India (NSE:ASTRAZEN) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹10,868.58, compared to a current price of ₹8,391.00 — trading 22.8% below its estimated fair value. The current ROCE % is 23.90% and 241.7% above the Drug Manufacturers industry median of 7.00. AstraZeneca Pharma India's overall GF Score™ is 92/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For AstraZeneca Pharma India (NSE:ASTRAZEN), the current ROCE % is 23.90% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is AstraZeneca Pharma India (NSE:ASTRAZEN) Overvalued in 2026?

Based on GuruFocus' analysis, AstraZeneca Pharma India stock appears to be undervalued. The current stock price of ₹8,391.00 is trading 22.8% below its estimated GF Value™ of ₹10,868.58. GuruFocus considers AstraZeneca Pharma India to be Modestly Undervalued.

Key valuation signals for NSE:ASTRAZEN:

  • ROCE %: 23.90%
  • GF Value™: ₹10,868.58 vs. price of ₹8,391.00 (22.8% below fair value)
  • GF Score™: 92/100 with 4 warning signs
  • Industry Position: 241.7% above the Drug Manufacturers median

No single metric tells the full story. See the NSE:ASTRAZEN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

AstraZeneca Pharma India Business Description

Other Exchanges 506820:India
Address Outer Ring Road, Block N1, 12th Floor, Manyata Embassy Business Park, Rachenahalli, Bangalore, KA, IND, 560 045
AstraZeneca Pharma India Ltd is engaged in the manufacture, trading, and marketing of pharmaceutical products. Its only operating segment is Healthcare. The company generates revenue from the sale of products such as Tablets, Injectables, and Inhalation. Geographically, it derives a majority of its revenue from India. It focuses on areas such as Cardiovascular, Renal and Metabolism (CVRM), Oncology, Respiratory, Inflammation, Autoimmunity, Neuroscience Infection and Vaccines. The company operates within India, and outside, like Cambridge, Gothenburg, and Gaithersburg. The majority of revenue is from India.
92GF Score

Get the complete analysis for NSE:ASTRAZEN

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹8,391.00
Price
₹10,868.58
GF Value